The Senate Finance Committee’s investigative report on insulin pricing covers familiar ground, given all the attention focused on the issue over the past few years. But its release just ahead of the official shift to Democratic control in the Senate is noteworthy because it marks the beginning of a new chapter in biopharma’s fight against legislative controls on drug pricing that will not include the protection of a Republican majority.
Released 14 January, the report caps a nearly two-year committee investigation into insulin pricing. It details sharp increases in list prices over the past decade, fed by escalating rebate demands from pharmacy benefit managers
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
